| Ytd | 12.90% | |
| 1y | 38.98% |
| Open | 11.61 | Prev Close | 11.72 | Low | 11.56 | High | 11.84 | Mkt Cap | 1.04B |
| Vol | 2.67M | Avg Vol | 1.81M | EPS | -3.37 | P/E | N/A | Forward P/E | -5.11 |
| Beta | 0.43 | Short Ratio | 6.19 | Inst. Own | 99.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 11.18 | 200-d Avg | 9.81 | 1yr Est | 32.00 |
KURA News
On Wednesday, Kura Oncology (NASDAQ:KURA) discussed second-quarter financial results during its earn
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Trans
Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor fo
– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova,
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial opera
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial opera
SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a
Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence an
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutica
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing
Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early co
The President and CEO acquired ~100,000 shares at $12.39 per share for a total transaction value of
Kura Oncology (KURA) gained attention today as CEO Troy Wilson bought another 100,000 shares for abo
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's
Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial res
Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform
Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's fi
The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock.
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other bi
Assenagon Asset Management S.A. lessened its stake in shares of Kura Oncology, Inc. (NASDAQ: KURA) b
Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% af
Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raise
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI
Kura Oncology (KURA) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Es
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.77) per share which beat the analyst co
– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approxi
– Publication details the discovery and preclinical characterization of ziftomenib, including its po
– Publication details the discovery and preclinical characterization of ziftomenib, including its po
SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a b
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and main
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus ca
Kura Oncology (NASDAQ:KURA) released first-quarter financial results and hosted an earnings call on
Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response r
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated an
Dow futures down 100 points. QuickLogic (QUIK) falls after reporting worse-than-expected Q1 results.
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.83) per share which beat the analyst co
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today
Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; anal
This whale alert can help traders discover the next big trading opportunities. Whales are entities w